pfizer–biontech fall 2023 vaccine  (BioNTech)

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Base case initial vaccine effectiveness values.

Article Snippet: For the base case of the current analysis, we assumed that the Moderna and Pfizer–BioNTech Fall 2023 vaccines are well-matched to the dominant circulating variant at the time.

Techniques: Infection

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Adverse event inputs.

Article Snippet: For the base case of the current analysis, we assumed that the Moderna and Pfizer–BioNTech Fall 2023 vaccines are well-matched to the dominant circulating variant at the time.

Techniques: Vaccines, Infection

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Base case (18+ general population): cost-effectiveness results.

Article Snippet: For the base case of the current analysis, we assumed that the Moderna and Pfizer–BioNTech Fall 2023 vaccines are well-matched to the dominant circulating variant at the time.

Techniques:

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Impact of scenario analyses on the projected incremental cost-effectiveness results with a COVID-19 vaccine updated for Fall 2023. Abbreviation in : CI: confidence interval; ICER: incremental cost-effectiveness ratio; ICU: intensive care unit; LB: lower bound; QALY: quality-adjusted life years; UB: upper bound; VE: vaccine efficacy.

Article Snippet: For the base case of the current analysis, we assumed that the Moderna and Pfizer–BioNTech Fall 2023 vaccines are well-matched to the dominant circulating variant at the time.

Techniques:

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Base case initial vaccine effectiveness values.

Article Snippet: Second, the Moderna Fall Campaign was compared to vaccination of individuals aged ≥18 years with the updated Pfizer–BioNTech COVID-19 mRNA Fall 2023 vaccine (Pfizer–BioNTech Fall Campaign).

Techniques: Infection

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Adverse event inputs.

Article Snippet: Second, the Moderna Fall Campaign was compared to vaccination of individuals aged ≥18 years with the updated Pfizer–BioNTech COVID-19 mRNA Fall 2023 vaccine (Pfizer–BioNTech Fall Campaign).

Techniques: Vaccines, Infection

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Base case (18+ general population): cost-effectiveness results.

Article Snippet: Second, the Moderna Fall Campaign was compared to vaccination of individuals aged ≥18 years with the updated Pfizer–BioNTech COVID-19 mRNA Fall 2023 vaccine (Pfizer–BioNTech Fall Campaign).

Techniques:

Journal: Vaccines

Article Title: The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan

doi: 10.3390/vaccines12040434

Figure Lengend Snippet: Impact of scenario analyses on the projected incremental cost-effectiveness results with a COVID-19 vaccine updated for Fall 2023. Abbreviation in : CI: confidence interval; ICER: incremental cost-effectiveness ratio; ICU: intensive care unit; LB: lower bound; QALY: quality-adjusted life years; UB: upper bound; VE: vaccine efficacy.

Article Snippet: Second, the Moderna Fall Campaign was compared to vaccination of individuals aged ≥18 years with the updated Pfizer–BioNTech COVID-19 mRNA Fall 2023 vaccine (Pfizer–BioNTech Fall Campaign).

Techniques:

Journal: medRxiv

Article Title: The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan

doi: 10.1101/2023.12.04.23299402

Figure Lengend Snippet: Impact of scenario analyses on the projected incremental cost-effectiveness results with a COVID-19 vaccine updated for Fall 2023

Article Snippet: Second, the Moderna Fall Campaign was compared to vaccination of individuals aged ≥18years with the updated Pfizer-BioNTech COVID-19 mRNA Fall 2023 vaccine (Pfizer-BioNTech Fall Campaign).

Techniques:

Journal: medRxiv

Article Title: The potential economic impact of the updated COVID-19 mRNA fall 2023 vaccines in Japan

doi: 10.1101/2023.12.04.23299402

Figure Lengend Snippet: Impact of scenario analyses on the projected incremental cost-effectiveness results with a COVID-19 vaccine updated for Fall 2023

Article Snippet: For the base case of the current analysis, we assumed that the Moderna and Pfizer-BioNTech Fall 2023 vaccines are well-matched to the dominant circulating variant at the time.

Techniques: